Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance. An important and consistent pathophysiological ®nding is the failure to produce adequate increments in insulin secretion in response to carbohydrate intake. Therefore, insulin secretagogue therapy, particularly when focused on prandial glucose regulation, is a logical approach to treatment because it addresses one of the most fundamental pathophysiological aspects of the disease. However, the traditional secretagogues Ð the sulphonylureas Ð have long been associated with the unwanted effect of hypoglycaemia. This is particularly likely to occur when drugs with lengthy plasma half-lives, prolonged drug ± receptor interactions, active metabolites or a reliance on renal clearance are used. The problem is most prevalent in elderly patients, where sulphonylurea-induced hypoglycaemia may be related to failure to comply with strict mealtimes or the need for supplementary food intake, often in the context of compromised renal function. Data from large-scale outcome studies demonstrate that when tight glycaemic control is achieved through aggressive antidiabetic therapy, late diabetic complications can be signi®cantly reduced. However, the pursuit of stricter HbA lc targets with more aggressive interventions may increase the risk of hypoglycaemia. This is an irony because the clinical need to avoid hypoglycaemia and patients' apprehension of it present barriers to the achievement of bene®cial glycaemic targets. However, an increased risk of hypoglycaemia may not be inevitable with insulin secretagogue therapy. The recently introduced carbamoylmethyl benzoic acid derivative, repaglinide, has pharmacological properties that are well suited to its intended role as a prandial glucose regulator. When taken prior to main meals, the rapid onset and relatively short duration of action of repaglinide aid disposal of the mealtime glucose load, without continued stimulation of pancreatic beta-cells in the postprandial fasting period. Repaglinide is also characterised by hepatic metabolism and elimination, which is an advantage in the context of impaired renal function. Prandial glucose regulation with repaglinide selectively increases insulin secretion, and hence limits glucose excursions, in the prandial phase. If a meal is omitted, so too is the corresponding dose. This more¯exible approach to the management of Type 2 diabetes has a number of advantages when compared with the ®xed daily dosing regimens of sulphonylureas, among them a reduced risk of hypoglycaemia Ð a bene®t that is particularly marked in the context of missed or irregular meals.
Introduction
The incidence of Type 2 diabetes is high and rising and is becoming a leading cause of mortality, morbidity and healthcare expenditure throughout the world. 1 Data from studies of intervention and outcome, such as the United Kingdom Prospective Diabetes Study (UKPDS), have shown that diabetic morbidity can be greatly reduced if blood glucose levels are well controlled. 2 Consequently, aggressive treatment of hyperglycaemia, with drug therapy when necessary, is to be encouraged. However, many patients with Type 2 diabetes are at risk of suffering adverse drug reactions with the intensi®ed usage of antidiabetic drugs. 3 In the case of the most widely used antidiabetic drugs in Type 2 diabetes, the sulphonylureas, the issue of greatest clinical concern is likely to be hypoglycaemia. Together with the increasing prevalence of Type 2 diabetes, this issue presents a major challenge to daily clinical practice.
Mild symptomatic hypoglycaemia can be unpleasant for the patient, but it is usually a temporary and manageable situation, as long as the patient is prepared and able to recognise the symptoms. However, if hypoglycaemia is undetected, ignored or develops rapidly, severe hypoglycaemia can arise. This is a life-threatening condition requiring hospitalisation for appropriate treatment. 4, 5 Furthermore, severe hypoglycaemia can pose diagnostic challenges, because it may present as a neurological condition such as hemiplegia. Without prompt diagnosis permanent neurological damage may result.
The traditional solution for avoiding this situation during sulphonylurea therapy has been to compel the patient to comply with a strict regimen of regular meals, supplemented by snacks. In this manner, the continuous hypoglycaemic action of the treatment is counteracted by exogenous glucose intake. Thus, treatment determines lifestyle rather than vice versa. Despite such advice, hypoglycaemia remains a familiar clinical problem, testifying, in part, to the dif®cul-ties that patients have in complying with this approach.
This review discusses the scale of the problem of hypoglycaemia with sulphonylureas, and some of the clinical consequences. In addition, the pharmacological pro®le and rationale for repaglinide, a novel insulin secretagogue designed for prandial glucose regulation, are reviewed in comparison to the sulphonylureas. Clinical evidence that compares the relative ef®cacy and risks of hypoglycaemia with these agents is also considered.
Drug-induced hypoglycaemia in Type 2 diabetes: how common?
Hypoglycaemia has long been recognised as a common and clinically important side effect associated with sulphonylurea therapy in Type 2 diabetes. Most events are symptomatic, so the patient is alerted to the acute need to supplement glucose intake. However, patient awareness of hypoglycaemia may diminish with the progression of diabetes and with repeated exposure to hypoglycaemia. 6 Severe hypoglycaemia resulting in hospitalisation or even death continues to be a clinical concern with sulphonylureas. Surprisingly perhaps, the scale of the problem has not been well quanti®ed. Early estimates of the incidences of symptomatic hypoglycaemia associated with sulphonylureas varied greatly Ð from 19 to 404 events per 1000 patient-years. 7, 8 Recent data, from the UKPDS, showed that 30% of patients treated with glibenclamide reported symptomatic hypoglycaemia during the ®rst year of therapy Ð the same incidence as was experienced among insulin-treated patients. 2 With time, the incidence of hypoglycaemia decreased with sulphonylurea therapy, but so too did glycaemic control, an observation that could be taken to imply a causal relationship. Over a ten year period, the mean annual incidences of patients experiencing at least one hypoglycaemic episode (of any intensity) were 11.0%, 17.7% and 36.5% with chlorpropamide, glibenclamide and insulin, respectively. The corresponding annual incidences of severe hypoglycaemic episodes among patients assigned to intensive blood glucose control were 1.0%, 1.4% and 1.8%.
Available evidence suggests that severe hypoglycaemic events are more likely to be protracted and to result in a fatal outcome when associated with sulphonylureas than with exogenous insulin. 4 One case study in Switzerland put the mortality rate for sulphonylurea-induced hypoglycaemic hospital admissions at 4.3% (CI, 1.9 ± 9.7%). 9 Life-threatening severe hypoglycaemia is most likely to arise when sulphonylureas that have long half-lives, active metabolites or a high degree of renal clearance are used in elderly patients, in patients with compromised renal function, or in cases where drug interactions are possible. Estimates vary as to the hospital admission rate for sulphonylurea-induced severe hypoglycaemia. The Swiss survey suggested an incidence of just 0.24 cases per 1000 patient-years, 9 while a Swedish study estimated the incidence to be 4.2 cases per 1000 patient-years Ð just 4% of the number of admissions for insulin-induced hypoglycaemia. 7 However, more recent data suggest the problem could be far more frequent. Surveys at individual hospitals in Hong Kong and South Africa showed sulphonylureas to be responsible for a much greater percentage of admissions for hypoglycaemia. 10, 11 In Hong Kong, sulphonylureas and insulin accounted for 29.7% and 13.5% respectively, of all admissions due to adverse drug reactions to prescribed doses of medication. Severe hypoglycaemia was the cause of 43% of these hospitalisations. 10 In the South African survey, one third of hypoglycaemic admissions were attributable to sulphonylureas. 11 The discrepancies between these and the earlier European studies may relate to the relatively lower use of sulphonylureas with long half-lives in Sweden and Switzerland. This hypothesis is supported by another Swiss survey of hospital admissions that showed sulphonylureas with long half-lives to be over-represented among admissions for hypoglycaemia. 12 It has also been suggested that the relatively greater use of longer-acting sulphonylureas, such as glibenclamide, may account for a relatively higher incidence of medical admissions for severe hypoglycaemia in Hong Kong in comparison to Singapore. 13 Increasing age, compromised renal function, irregular meals: the key risk factors for hypoglycaemia It has been reported that 95% of sulphonylurea-related hospital admissions for hypoglycaemia have involved patients over the age of 60 y, with 52% of these patients having impaired renal function. 10 A high mean age also characterised a series of glibenclamide-treated patients with Type 2 diabetes in whom severe hypoglycaemia was reported to the Swedish Adverse Drug Reactions Advisory Committee.
14 In this study, 24 of the 57 patients reviewed had protracted hypoglycaemia, and 10 patients died. In some cases, fatal outcomes occurred when doses were as low as 2.5 ± 5 mgaday. Protracted hypoglycaemia with occasional fatal outcomes has also been reported in association with glipizide, especially in the situation of advanced age andaor renal impairment. 15 The commonest precipitating event for severe hypoglycaemia that has been identi®ed is missed or irregular meals. In the South African study, 36% of hospital admissions for hypoglycaemia were attributable to missed meals. 11 Decreased food intake was also the most common of the identi®ed causal events leading to severe hypoglycaemia in a recent Swiss survey, being cited in 32% of cases. 12 Despite these well-known risks, the long-acting sulphonylureas continue to enjoy widespread use, largely because of their proven antidiabetic ef®cacy. For example, it has been estimated that in Germany more than 50% of patients with Type 2 diabetes receive sulphonylureas, and of these 90% receive glibenclamide. 12 Such agents are often used inappropriately. Surveys of antidiabetic treatments in Type 2 diabetes show the majority of glibenclamide-treated patients to have predisposing risk factors for hypoglycaemia, such as being aged over 65 y, living alone, or having renal or cognitive impairment. 3, 16 Hypoglycaemia as a barrier to compliance and control Hypoglycaemia is a real and a perceived threat for patients taking hypoglycaemic agents. The clinical need to avoid the morbid consequences of hypoglycaemia can be regarded as an immediate barrier to the achievement of euglycaemia. 17 Studies involving patients with Type 1 diabetes have shown that the fear of recurring severe hypoglycaemia can also act as a barrier to control. This anxiety can cause considerable mental distress to the patient and close family members, impacting quality of life.
18 ± 22 A consequence of this fear is that compliance to antidiabetic treatment may be jeopardised as the patient adopts avoidance behaviours. 21 Evidence in support of this concern is again forthcoming from studies in Type 1 diabetes, where a history of hypoglycaemia has been associated with greater patient acceptance of poor levels of metabolic control. 23, 24 Spouses, fearful of hypoglycaemic episodes in their diabetic partners, may be in¯uential in such situations. 22 Anxieties among patients and family members are not without foundation. Patients' perceived symptoms of hypoglycaemia have been shown to be a poor indicator of objectively measured blood glucose levels, 6, 25 and there is evidence that the likelihood of patients becoming unaware of hypoglycaemia may increase as diabetes and autonomic neuropathy progresses. 6 The issue of patients with Type 2 diabetes deliberately under-dosing their oral antidiabetic agents in order to avoid hypoglycaemia remains to be investigated. However, the DCCT and UKPDS ®nding that there appears to be no threshold for glycaemic control below which the patient's long-term prognosis cannot be further improved 2, 26 has raised the stakes in terms of the clinical signi®cance of compliance with treatment. Thus, fear of hypoglycaemia leading to poor compliance may put patients at an unnecessarily high long-term risk from their diabetes. Indeed, despite the epidemiological evidence concerning outcome, a survey of patients with Type 2 diabetes suggested that many are more concerned about their short-term symptoms than their long-term prognosis, adopting limited levels of compliance aimed at remaining symptom free. 27 Patients who were aware of potential diabetic complications, and even the incidences of these, often had dif®culty in attaching personal signi®cance to these risks. It can therefore be anticipated that antidiabetic treatments associated with a reduced risk, and hence reduced fear of hypoglycaemia, could aid compliance and help the patient to achieve bene®cial targets for blood glucose control.
So why insulin secretagogue therapy in Type 2 diabetes?
Although the risk of hypoglycaemia may seem inherent in treatments designed to raise plasma insulin levels, there are compelling reasons for considering insulin secretagogues in the treatment of Type 2 diabetes. These relate to the pathophysiology of the disease itself and to the limitations of alternative treatment methods.
Type 2 diabetes is characterised by abnormal pancreatic beta-cell function, often in association with insulin resistance. This situation arises as the beta-cell fails to detect or respond to changes in plasma glucose concentration andaor fails to compensate for insulin resistance by increasing insulin output. 28, 29 In Type 2 diabetes, insulin secretion is always de®cient relative to the prevailing blood glucose concentration, 28 and in severe disease this de®ciency becomes absolute in comparison to healthy controls. The greatest discrepancies between insulin secretion and metabolic need are consistently found in the prandial setting, during which time the early phase of the insulin response is delayed and diminished in comparison to healthy controls ( Figure 1) . 28, 30, 31 The early phase of the prandial insulin response is instrumental in the suppression of endogenous glucose production, so in Type 2 diabetes endogenous glucose production continues in spite of prandial intake and a continued relative insuf®ciency of insulin output, resulting in postprandial hyperglycaemia. 28,30,32 ± 34 This situation can also be detected in individuals with impaired glucose tolerance, 33, 35 implying that failure to produce increments in insulin output suf®cient to counteract increments in blood glucose is a pivotal, early pathophysiological component of Type 2 diabetes. The initial manifestations are excessive postprandial glucose excursions, but as the situation becomes further decompensated, chronic elevation of basal glucose (and sometimes basal insulin) ensues.
Given these metabolic derangements, the most logical, and likely optimal approach to the treatment of Type 2 diabetes would be to increase insulin levels early in the prandial phase, either through the use of secretagogues that accelerate glucose-mediated insulin output, or the less physiological measure of prandial subcutaneous insulin substitution. These methods counteract a fundamental de®cit of Type 2 diabetes Ð prandial insulin de®ciency.
In contrast, antidiabetic agents that increase insulin sensitivity or delay glucose absorption do not address this fundamental de®cit, although their actions may be complementary in the setting of marked insulin resistance. Indeed, the ef®cacy of insulin-sensitising agents, such as the thiazolidinediones, is dependent on there ®rst being a suf®ciency of plasma insulin, the result being that these agents are often ineffective as monotherapy. 36 Metformin may be more effective as monotherapy than the thiazolidinediones, because it additionally suppresses endogenous glucose output, but again its action does not address the fundamental prandial insulin de®cit. Indeed, supraphysiological postprandial glucose excursions during metformin therapy have been reported. 37 Furthermore, the renal elimination and gastrointestinal side effect pro®le of metformin preclude its use in many patients, including those most at risk from sulphonylurea therapy. 38 The alpha-glucosidase inhibitor, acarbose, while delaying the absorption of prandial carbohydrates, has been reported to have only a minimal impact on HbA lc (a reduction of 0.5 percentage points in the UKPDS) when used as monotherapy. 39, 40 This may relate, in part, to poor tolerability of recommended doses. The delayed absorption of carbohydrates with alpha-glucosidase inhibition gives rise to frequent gastrointestinal side effects.
The ability of sulphonylureas to improve parameters of glycaemic control is well documented. In the UKPDS, monotherapy with sulphonylureas was associated with a greater success rate than metformin in terms of achieving and maintaining HbA lc targets. 41 Unfortunately however, these traditional insulin secretagogues have been unable to selectively increase plasma insulin levels only at times of physiological necessity, hence the associated risks of hypoglycaemia.
Hypoglycaemic agents: expectations for risk and control
Studies of treatment regimens designed to achieve more rigorous control of blood glucose have generally shown improved control (as assessed by markers such as HbA lc ) to come at the price of an increased risk of hypoglycaemia. 2, 42 Such data may have fuelled the perception that the risk of hypoglycaemia is inevitable with effective hypoglycaemic therapy, but, in part, this association merely re¯ects the pharmacokinetic properties of the treatments used. There is no reason why the risk of hypoglycaemia could not be minimised without compromising glycaemic control if dynamic physiological blood insulin pro®les could be recreated using treatments with improved pharmacological properties.
An important consideration in the pursuit of such a goal is that the ideal`physiological' insulin pro®le will vary on a day-by-day basis. The risk of hypoglycaemia is increased by a number of circumstances including reduced in¯ux of exogenous glucose, increased utilisation of endogenous glucose, decreased production of endogenous glucose, increased sensitivity to insulin and decreased insulin clearance. 17 Events that might precipitate such circumstances include overnight fasting, missed meals, physical exercise, alcohol consumption or impaired renal function. Therefore, it is desirable that administration of exogenous insulin or iatrogenic stimulation of endogenous insulin secretion should be appropriately timed on a day-by-day basis to minimise the impact of such threats. Modern regimens involving Prandial glucose regulation in Type 2 diabetes M Nattrass and T Lauritzen exogenous insulins Ð notably, the basal bolus approach Ð are intimately linked to the patient's meal consumption. 31 Using this approach, patients are free to vary the number of meals or the times at which they are taken, and injections can be timed to mimic the rapid, early rise in insulin secretion characteristic of the prandial response in health. In addition,¯exible treatment regimens have the potential to allow patients to compensate for other daily events such as high levels of physical exertion. 31 However, traditional regimens of sulphonylureas are in¯exible Ð the patient is obliged to modify his or her lifestyle to maximise the bene®ts and minimise the risks of therapy. Sulphonylurea-treated patients must pay careful attention to eating patterns; a strict mealtime regimen may be prescribed with the patient required to consume regular snacks between meals. Not only does this situation place restraints on the patient's routine and activities, it may also compromise their ability to reduce caloric intake and weight. 31 This is ironic; once-daily dosing regimens of oral hypoglycaemic agents were developed with the intention of minimising lifestyle disruption, whereas in practice they have had the opposite effect. Just as the approach to managing Type 1 diabetes has moved towards¯exible preprandial injection regimens, so a more re®ned and less disruptive treatment approach in Type 2 diabetes might require preprandial dosing with shorter-acting hypoglycaemic agents.
Conventional hypoglycaemic agents: kinetic limitations
The in¯exible dosing and disciplined approach to glucose intake required for successful sulphonylurea treatment is dictated largely by the pharmacokinetic properties of these agents. A major limitation is that their duration of action extends beyond mealtimes into periods when blood glucose may no longer be elevated if prandial glucose disposal has been successful. For example, glibenclamide, at recommended doses, has a very long duration of action with a mean elimination half-life of 15 hours. Its two major metabolites are pharmacologically active insulin secretagogues, and at low concentrations the magnitude and duration of their action may exceed those of the parent compound. 43 Even shorter-acting sulphonylureas, such as glipizide, with a half-life of 1 ± 5 h, 44 have recommended dosing regimens designed to maintain plasma drug concentrations across dosing intervals that are known to have an insulin secretagogue activity Ð regardless of the patient's residual beta-cell function. Inappropriate stimulation of insulin secretion during times of low blood glucose concentration in the absence of exogenous glucose in¯ux will inevitably increase the risk of hypoglycaemia. This risk will also be compounded when sulphonylureas that are renally excreted (or that have renally-excreted active metabolites) are used in patients with compromised renal function. 45 Food intake may also adversely affect the temporal pro®le of stimulated insulin secretion during sulphonylurea therapy. Single dose studies have shown 2.5 mg of glibenclamide taken 30 min before breakfast to be more effective than 7.5 mg taken with breakfast, 46 while concomitant food intake has been shown to delay the absorption of glipizide. 47 There is also evidence that hyperglycaemia itself can delay the absorption of glipizide. 48, 49 Consequently, if dosing is ill-timed, sulphonylureas may be at their least potent when the physiological need for insulin is greatest and vice versa. It has thus been argued that they should be administered at an appropriate time before the intake of food to allow for delays in drug absorption and drug ± receptor interaction. 43 A further issue to consider is that the long-term administration of sulphonylureas with long elimination half-lives causes continuous rather than discontinuous drug ± receptor interaction. That is, the minimum effective concentration of the drug is exceeded across dosing intervals and throughout each 24-h period. 43 During long-term administration, low doses of short-acting sulphonylureas are associated with predictable and sustained relationships between plasma drug concentration and stimulated insulin secretion, provided drug levels return to zero by the end of a dosing interval. In contrast, the protracted use of long-acting sulphonylureas has been associated with loss of the negative correlation between the plasma drug and fasting glucose concentrations. 43 To some extent, this effect may be due to hyperglycaemia ± mediated delays in drug absorption, but the possibility of down-regulation of beta-cell sensitivity with continuous drug exposure must also be considered. Indeed, there is evidence that the hypoglycaemic effect of sulphonylureas is diminished with continuous exposure, but is restored by drug-free intervals. 43, 50 Under these circumstances, erratic dosing of sulphonylureas by poorly-compliant patients could be a further cause of increased hypoglycaemic risk.
Finally, recent in vitro data indicate that sulphonylureas may stimulate beta-cells to secrete insulin regardless of the prevailing extracellular glucose concentration, with their secretagogue action being in part mediated by a direct effect upon the cellular exocytotic apparatus. 51, 52 This ®nding implies that stimulated insulin secretion will not be curtailed during periods of hypoglycaemia. It also raises concerns about whether sulphonylureas have exocytotic actions in secretory cells of the endocrine system other than pancreatic beta-cells.
Prandial glucose regulation: stimulated insulin release Ð when needed
An alternative approach that is gaining favour for glycaemic management in patients with Type 2 Prandial glucose regulation in Type 2 diabetes M Nattrass and T Lauritzen diabetes, is the use of rapid-onset, short-acting insulin secretagogues given¯exibly at mealtimes. This approach, known as prandial glucose regulation, has a number of theoretical advantages. As discussed above, glucose regulation in Type 2 diabetes is most compromised during the prandial phase, so it is both logical and`physiological' to selectively limit blood glucose excursions at these times. Indeed, elevation of basal glucose (and insulin) in Type 2 diabetes is largely a consequence of the failure to regulate prandial glucose. That effective disposal of prandial glucose will also maintain glycaemic control during fasting periods is well demonstrated by the simple observation that when patients with Type 2 diabetes are deprived of food for a few days, their blood glucose levels rapidly reduce to normal levels, maintained for the duration of caloric restriction. 53, 54 On recommencing a normal diet, the pre-breakfast blood glucose readings return to hyperglycaemic levels. In these studies, insulin levels also declined alongside glucose during the fasting periods and insulin sensitivity increased in obese individuals subsequent to the normalisation of basal blood glucose levels. Thus, in the setting of residual beta-cell function, the`fasting' hyperglycaemia of Type 2 diabetes can be seen as primarily the legacy of a failure to dispose of the previous day's prandial glucose.
Another issue arguing in favour of selective regulation of prandial glucose is that postprandial glucose excursions may contribute directly to adverse diabetic outcomes. 55 ± 59 Recent epidemiological data show that the risks of diabetes-related vascular morbidity and mortality are more closely correlated with postprandial than fasting hyperglycaemia. 60 ± 62 Effective prandial glucose regulation may therefore not only improve overall glycaemic control (including fasting blood glucose levels), but also be the best strategy for improving prognosis.
In summary, as part of an overall management plan involving lifestyle, diet and exercise, prandial glucose regulation seeks to correct a fundamental metabolic defect in Type 2 diabetes. Importantly, by selectively augmenting insulin release during times of elevated blood glucose, the risk of hypoglycaemia can be reduced. In turn, the patient is afforded more freedom in eating patterns and caloric intake, and a greater freedom from anxiety Ð bene®ts that may also be expected to enhance compliance.
Effective prandial glucose regulation: what pharmacological properties are needed?
There are a number of pharmacological properties required of an effective prandial glucose regulator. It should have an onset of action that is suf®ciently rapid to inhibit endogenous hepatic glucose output in the prandial phase. The drug ± receptor interaction should occur without delay, but should not be maintained into fasting periods. The duration of action should therefore be short, although of suf®cient extent to adequately dispose of the exogenous glucose load. Only with this combination of properties will it be possible to offer the patient genuine¯exibility in their meal pattern. Hypoglycaemia is a risk of too long a duration of action, but too short an action may result in failure to control fasting blood glucose with¯exible prandial dosing. For example, early data with the insulin secretagogue, nateglinide, suggest that fasting blood glucose is only brought under control when patients take three main meals per day supplemented by a late evening snack, with a full dose taken at each of these four occasions. 63 Thus, mealtime¯exibility is compromised.
In addition, the ideal prandial glucose regulator should be metabolised to inactive metabolites, and should not accumulate in the situation of impaired renal function. Finally, desirable kinetic properties should not be compromised by ingestion of food.
Repaglinide: the ®rst hypoglycaemic prandial glucose regulator
Drugs with the necessary properties for prandial glucose regulation were not available until repaglinide, a carbamoylmethyl benzoic acid (CMBA) derivative, was exclusively developed and introduced for this role. Repaglinide is taken prior to main meals to stimulate insulin secretion at the most appropriate times. Like the sulphonylureas, it acts by depolarising the pancreatic beta-cell membrane by blocking ATPgated potassium channels, thereby stimulating insulin secretion. However, in contrast to the sulphonylureas, repaglinide does not stimulate insulin release independently of its effects on beta-cell potassium channels, and does not inhibit insulin biosynthesis. 51, 52, 64, 65 Another pharmacological difference of potential clinical importance between repaglinide and the sulphonylureas is that repaglinide augments insulin release from pancreatic islets in vitro only in the presence of glucose. 51, 66 Thus, repaglinide enhances glucosemediated insulin release, and hence may be less likely to cause hypoglycaemia.
The pharmacokinetic characteristics of repaglinide can also be expected to minimise risks of hypoglycaemia. Repaglinide has a rapid onset and short duration of action, reaching maximum plasma concentrations 50 min after oral dosing with a terminal elimination half-life of just 32 min. 67 These kinetic properties are similar whether repaglinide is taken 30 min in advance of, or immediately before a meal. Repaglinide is extensively metabolised in the liver to inactive metabolites that are primarily excreted in bile. 68 Consequently, the kinetics of repaglinide are unaffected by mild to moderate renal dysfunction in Prandial glucose regulation in Type 2 diabetes M Nattrass and T Lauritzen patients with Type 2 diabetes. 69 As repaglinide is therefore unlikely to accumulate in patients who have or who develop this impairment, another recognised cause of hypoglycaemia can be avoided.
Repaglinide in clinical practice
The ability of meal-based regimens of repaglinide to achieve metabolic control at least as effectively as alternative antidiabetic agents has been demonstrated in a series of trials. Signi®cant improvements in markers of glycaemic control associated with repaglinide treatment have been demonstrated in placebocontrolled studies, 70 ± 72 while clinical trials have shown repaglinide to be at least as effective an antidiabetic as comparators such as glibenclamide 73 ± 75 and metformin, 76 and superior in ef®cacy to glipizide 77 and troglitazone. 78 Comparative studies have also shown that repaglinide-treated patients are at lower risk from hypoglycaemia in comparison to patients receiving sulphonylureas, although the patient-reported incidences of symptomatic mild hypoglycaemia have often been similar. 73, 74 However, patients' perceptions of hypoglycaemia are not always indicative of their blood glucose levels, as noted above, and this parameter does not provide information about between-treatment differences in blood glucose nadirs. In a prospective, randomised, 1-y study of 576 patients with Type 2 diabetes, 15% of patients receiving repaglinide and 19% receiving glibenclamide reported symptoms of hypoglycaemia. 74 While this difference in incidence was not signi®cant, self-assessed blood glucose levels measured at the time of hypoglycaemic symptoms were signi®cantly lower (P 0.004) in patients receiving glibenclamide than in those receiving repaglinide (Figure 2 ).
Another year-long comparative trial of repaglinide and glibenclamide involving 424 patients reported low incidences of symptomatic hypoglycaemia: 9% in each group. 73 Again, however, objective data from self-assessments of blood glucose showed an advantage for repaglinide-treated patients, with pre-lunch blood glucose readings of`4.4 mmolal recorded by 21% of glibenclamide-treated patients and only 9% of repaglinide-treated patients.
These comparative trials were designed to assess ef®cacy in terms of metabolic control, and were not statistically powered to detect between-treatment differences in the incidences of hypoglycaemia. Signi®-cant differences in incidences of severe hypoglycaemia do emerge however, when pooled data from comparative studies involving repaglinide and sulphonylureas are examined. These data, representing more than 1000 patients, show that despite identical levels of metabolic control determined by HbA lc , treatment with repaglinide incurs an absolute risk reduction of 60% for major hypoglycaemia in comparison to treatment with a sulphonylurea. 79 The incidences of severe episodes of hypoglycaemia (de®ned as subjective symptoms with concomitant blood glucose`2.5 mmolal) were, respectively, 1.3% and 3.3% for repaglinide-and sulphonylureatreated patients in this analysis (P 0.03) (Figure 3 ). Another analysis of these data, in which objective measurements of blood glucose were obtained, showed the relative risk of major hypoglycaemia to be two-fold higher with glibenclamide and glipizide, and four-fold higher with gliclazide, in comparison to repaglinide. 68 Examination of the distribution of glucose levels measured at the time of symptomatic hypoglycaemia revealed that most reports with repaglinide were made with blood glucose levels in excess of 3.3 mmolal. 79 In contrast, most incidences of hypoglycaemia reported during sulphonylurea treatment occurred with blood glucose levels below 3.3 mmolal (Figure 4) . The reason for this discrepancy is unclear, but the possibility of patients having a relatively higher threshold for hypoglycaemic awareness during repaglinide therapy, perhaps relating to a reduced total nocturnal burden of hypoglycaemia, needs to be considered. This observation is consistent with the data concerning glucose nadirs discussed above. 
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It should be noted that these comparative studies were conducted according to strict protocols with dosing and food consumption controlled according to the requirements of sulphonylurea therapy.`In¯ex-ible' treatment regimens were followed, ie repaglinide was not utilised as a¯exible prandial glucose regulator, and compared as such with the empirical use of sulphonylureas. Consequently, the relative everyday risks associated with sulphonylureas may have been underestimated in these comparisons. However, the relative safety of¯exible dosing with repaglinide in the context of a missed meal was clearly demonstrated in a randomised study in which 43 patients with wellcontrolled Type 2 diabetes received either repaglinide with meals or glibenclamide given according to label recommendations. 80 These patients were subsequently assessed with and without omission of their midday meal; those receiving repaglinide also omitted their midday dose when lunch was withheld, according to the prandial glucose regulation strategy. In this study, omission of lunch did not affect the mean minimum blood glucose level in repaglinide-treated patients, which remained unchanged at 4.3 mmolal. In contrast, omission of lunch in glibenclamide-treated patients led to a fall in the mean blood glucose nadir from 4.3 to 3.4 mmolal (between-group difference, P 0.014). Six episodes of hypoglycaemia (four requiring treatment) were reported, all in glibenclamide-treated patients and all in association with omission of lunch. The good tolerability and ef®cacy pro®le of the¯exible dosing strategy was also demonstrated in a placebo-controlled study. 71 Patients took repaglinide at mealtimes but chose to have either two, three or four meals per day. Regardless of the meal pattern, repaglinide was associated with signi®cantly better glycaemic control than placebo. Importantly, no cases of severe hypoglycaemia were reported, and the risk of mild symptomatic hypoglycaemia was independent of the meal pattern chosen.
Comparisons with placebo show that while the risk of hypoglycaemia with repaglinide may have been reduced relative to sulphonylureas, it has not been eliminated, notwithstanding the possibility that patients may have a greater sensitivity to hypoglycaemia when treated with repaglinide rather than sulphonylureas (Figures 2 and 4) . Pooled data from clinical trials representing over 1200 patient-years of repaglinide exposure, have shown 16% of repaglinide-treated patients to have reported symptomatic hypoglycaemia during monotherapy. 68 In one 18-week, placebo-controlled study, the incidence of reported hypoglycaemia among 66 repaglinide-treated patients was 36% (vs 6% with placebo), but only one event was associated with a blood glucose level`2.5 mmolal. 70 In common with other studies, most hypoglycaemic events tended to occur during initial dose-adjustment. A 24-week placebo-controlled study showed the incidence of hypoglycaemia to be 11% in the placebo group, and 27% and 35% in patients receiving prandial repaglinide doses of 1 mg and 4 mg, respectively. 72 However, there were no severe hypoglycaemic events among 286 repaglinidetreated patients, and the overall discontinuation rates (6% and 8% at 1 mg and 4 mg doses, respectively) were lower than in the placebo group (11%). Similarly, in another placebo-controlled study, in which repaglinide was taken by more than 200 patients over 16 weeks, minor hypoglycaemia was reported by 17% of repaglinide-treated patients and 2% of patients receiving placebo, but in no cases was hypoglycaemia severe. 71 In summary, it appears that the frequency and intensity of hypoglycaemic events are indeed reduced in repaglinide-treated patients relative to sulphonylurea-treated patients, even with well-disciplined drug dosing and food consumption, while in everyday clinical usage this advantage may be enhanced. This risk reduction is achieved without any loss in antidiabetic ef®cacy.
Repaglinide in combination therapy
The relative risk of hypoglycaemia during antidiabetic combination therapy is an area of clinical importance, as the pursuit of more rigorous glycaemic targets together with the progressive nature of Type 2 diabetes will necessitate an increasing use of combination regimens. 41 Insulin secretagogues can be combined logically with either insulin sensitising agents or exogenous insulin in an attempt to maintain tight glycaemic control. To date, repaglinide has been studied in combination with troglitazone, metformin and basal NPH insulin, but there are as yet no comparative data to determine the relative risks of hypoglycaemia with these versus alternative combination regimens.
A study of 256 patients with Type 2 diabetes suggested that the risk of hypoglycaemia is not increased when repaglinide is combined with the Prandial glucose regulation in Type 2 diabetes M Nattrass and T Lauritzen thiazolidinedione troglitazone despite signi®cantly better glycaemic control being achieved with this combination than with either agent used as monotherapy. 78 The incidences of symptomatic hypoglycaemia con®rmed by self-assessed blood glucose readings 2.5 mmolal were 3%, 6% and 5% during treatment with troglitazone, repaglinide and the combination of the two agents, respectively.
The incidence of hypoglycaemia may, however, be increased when repaglinide is used in combination with metformin. In a study of 83 patients with Type 2 diabetes who were previously poorly controlled by metformin as monotherapy, 33.3% of those randomised to combination therapy (nine patients) reported a total of 30 symptomatic hypoglycaemic events, representing 3.2 events per patient per year. 76 In comparison, 10.7% of patients (three patients reporting nine events) randomised to repaglinide monotherapy experienced hypoglycaemia, representing 0.97 events per patient per year (P`0.05). No patients receiving metformin monotherapy experienced hypoglycaemia. Combination therapy was, however, associated with a signi®cant improvement in glycaemic control in this patient population, and one individual accounted for 12 of the hypoglycaemic events reported in the combination group. Blood glucose measurements were obtained during 87% of the hypoglycaemic events. In half of these, blood glucose was in excess of 3.5 mmolal and in only four cases was it at, or below, 2.8 mmolal. None of the hypoglycaemic events in the study were reported as severe. Therefore, given repaglinide's superiority over sulphonylureas in terms of hypoglycaemic risk, it can be anticipated that a repaglinide-metformin combination may have a more favourable risk : bene®t ratio than a sulphonylurea-metformin combination.
Prandial repaglinide has also been assessed in combination with basal bedtime NPH insulin in a study of 83 patients with Type 2 diabetes developing secondary failure to sulphonylureas. 81 This study demonstrated a bene®cial impact on glycaemic control when combination therapy was used in poorlycontrolled patients, and again this bene®t was achieved without an unacceptable increase in the risk of hypoglycaemia. Symptomatic hypoglycaemic episodes were reported by 25.9% of patients receiving combination therapy, 11.1% of patients receiving NPH insulin as monotherapy and none of the patients receiving repaglinide as monotherapy. Although the incidence of symptomatic hypoglycaemia was increased in association with combination therapy, the only episode of hypoglycaemia recorded as severe (blood glucose level, 3.1 mmolal) occurred in the insulin monotherapy group.
Conclusion
It is now clear that the prognosis for patients with Type 2 diabetes can be greatly improved when rigorous targets for indices of glycaemic control are met. Sulphonylureas have well-documented antidiabetic ef®cacy, but the hypoglycaemia associated with these agents remains a serious concern for patients, their family members and clinicians. The clinical need to avoid hypoglycaemia, and the patient's fear of the condition, are formidable barriers when it comes to achieving targets of metabolic control known to be bene®cial. However, the counter-measures necessary to avoid hypoglycaemia place restrictions on patients' lifestyles. Yet, hypoglycaemia is not an inevitability; the risk stems largely from the pharmacokinetic limitations of traditional treatment methods. The use of exogenous insulin or insulin secretagogues could become hazard-free if dynamic methods could be found to recreate truly physiological blood insulin pro®les.
The modern concept of managing glycaemic control in Type 2 diabetes through prandial glucose regulation attempts to recreate such¯exible, physiological blood insulin pro®les. Prandial glucose regulation provides an opportunity to achieve a high degree of metabolic control without incurring an undue risk of hypoglycaemia. Repaglinide is the only insulin secretagogue currently available with the necessary pharmacological properties for this role. The clinical evidence suggests that, while the risk of hypoglycaemia is not eliminated, the incidence and severity of hypoglycaemic events will be signi®cantly reduced when prandial repaglinide is used in preference to ®xed-dose regimens of traditional sulphonylureas. The impact of using prandial repaglinide in place of standard sulphonylurea regimens on nocturnal hypoglycaemia requires elucidation, as does the possibility that patients may be able to detect hypoglycaemia at higher thresholds of blood glucose levels when treated with repaglinide.
Type 2 diabetes is increasing rapidly in prevalence. The emphasis on its treatment is moving towards aggressive interventions aimed at strict glycaemic control Ð an approach that is expected to increase patient longevity and inhibit the progression of diabetic complications. In this context, new antidiabetic therapies associated with preserved ef®cacy but low risks of hypoglycaemia are to be welcomed.
